Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-05 (theglobeandmail.com)
Cutaneous Lupus Erythematosus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies -
DelveInsight's, "Cutaneous Lupus Erythematosus Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the Cutaneous Lupus Erythematosus Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous Lupus Erythematosus Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Read more
2025-05-05 (investing.com)
H.C. Wainwright lowers price targets Biogen to $ 187, maintains purchase advice by .com
H.C. Wainwright lowers price targets Biogen to $ 187, maintains purchase advice
Read more
2025-05-05 (thepharma.media)
Biogen quarterly profit exceeded forecasts due to success in the segment of orphan diseases - Media
At the same time, the company activated efforts to promote existing drugs and has recently acquired new assets.
Read more
2025-05-05 (pharmabiz.net)
STATE: PUJA BETWEEN SPINRAZA AND LIGONUX -
Nusinersen, the treatment for spinal muscular atrophy, stars in a new public purchase. And for the first time, there are two different options for their acquisition. See tender so far, the only therapeutic option carried the signature of the American Biogen, which was presented with its eminraza treatment. However, in October […]
Read more
2025-05-02 (tipranks.com)
Biogen price target lowered to $205 from $217 at RBC Capital - TipRanks.com
RBC Capital lowered the firm's price target on Biogen (BIIB) to $205 from $217 but keeps an Outperform rating on the shares. The company's Q1 results reaffirm that ...
Read more
2025-05-02 (scientistlive.com)
Alzheimer's medication approved by European Commission | Scientist Live
The medication designed for mild cognitive impairment or mild dementia due to Alzheimer's.
Read more
2025-05-02 (smartkarma.com)
Strategic Reviews, Company Sales, and Litigation: Analyzing Active Portfolio Ideas - Special Situation Investments
Lifeway Foods is likely to be sold to Danone, with a potential 14%+ upside, following board changes. Sage Therapeutics rejected Biogen's offer...
Read more
2025-05-02 (investing.com)
Canaccord reduces the target price of Biogen shares to $ 220, preserving the rating "Buy" from Investing.com
Canaccord reduces the target price of Biogen shares to $ 220, preserving the "Buy" rating
Read more
2025-05-02 (devdiscourse.com)
Global Health Landscape: From Vaccine Innovation to Regulatory Battles | Science-Environment
Recent health news spotlights include Cardinal Health's robust growth forecast despite tariffs, CVS's strategy shifts, Biogen's resilience in rare disease markets, and novel treatments advancements by J&J. Additionally, regulatory and funding challenges faced by WHO and the U.S. emphasize the complex dynamics shaping global healthcare.
Read more
2025-05-01 (poetsandquants.com)
| 2025 Best and Brightest MBA: Maria Raffaella Guerrero Romero, Boston University (Quaestrom)
Maria Rafaella Guerrero Romero, who is graduating from Boston University, has been named a Poets&Quants Best & Brightest MBA for 2025
Read more
2025-05-01 (biopharmadive.com)
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda |
Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics production plant.
Read more
2025-05-01 (investing.com)
Stifel maintains the "Hold" recommendation for Biogen shares with a target price of $ 144 via Investing.com
Stifel maintains the "Hold" recommendation for Biogen shares with a target price of $ 144
Read more